This is the peer reviewd version of the followng article:

Extracellular matrix mechanical cues regulate lipid metabolism through Lipin-1 and SREBP / Romani, Patrizia; Brian, Irene; Santinon, Giulia; Pocaterra, Arianna; Audano, Matteo; Pedretti, Silvia; Mathieu, Samuel; Forcato, Mattia; Bicciato, Silvio; Manneville, Jean-Baptiste; Mitro, Nico; Dupont, Sirio. - In: NATURE CELL BIOLOGY. - ISSN 1465-7392. - 21:3(2019), pp. 338-347. [10.1038/s41556-018-0270-5]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

01/05/2024 19:18

1	Manuscript NCB-D36852
2	
3	Extracellular matrix mechanical cues regulate lipid metabolism through Lipin-1 and SREBP
4	
5	Patrizia Romani <sup>1</sup> , Irene Brian <sup>1</sup> , Giulia Santinon <sup>1</sup> , Arianna Pocaterra <sup>1</sup> , Matteo Audano <sup>2</sup> , Silvia Pedretti <sup>2</sup> ,
6	Samuel Mathieu <sup>3,4</sup> , Mattia Forcato <sup>5</sup> , Silvio Bicciato <sup>5</sup> , Jean-Baptiste Manneville <sup>3,4</sup> , Nico Mitro <sup>2</sup> & Sirio
7	Dupont <sup>1</sup> *
8	
9	<sup>1</sup> Department of Molecular Medicine (DMM), University of Padua, Padua, Italy
10	<sup>2</sup> Department of Pharmacological and Biomolecular Sciences (DiSFeB), University of Milan, Milan,
11	Italy
12	<sup>3</sup> Institut Curie, PSL Research University, CNRS UMR144, Paris, France
13	<sup>4</sup> Sorbonne Universités, UPMC University Paris 06, CNRS UMR144, Paris, France
14	<sup>5</sup> Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
15	
16	*correspondence: sirio.dupont@unipd.it
17	

Extracellular matrix (ECM) mechanical cues have powerful effects on cell proliferation, 18 19 differentiation and death. Here, starting from an unbiased metabolomics approach, we identified synthesis of neutral lipids as a general response to mechanical signals delivered by cell-matrix 20 21 adhesions. Extracellular physical cues reverberate on the mechanical properties of the Golgi 22 apparatus and regulate the Lipin-1 phosphatidate phosphatase. Conditions of reduced 23 actomyosin contractility lead to inhibition of Lipin-1, accumulation of SCAP/SREBP to the Golgi 24 apparatus and activation of SREBP transcription factors, in turn driving lipid synthesis and 25 accumulation. This occurs independently of YAP/TAZ, mTOR and AMPK, and in parallel to the 26 feedback control by sterols. Regulation of SREBP can be observed in a stiffened diseased tissue, 27 and contributes to the pro-survival activity of ROCK inhibitors in pluripotent stem cells. We 28 thus identify a general mechanism centered on Lipin-1 and SREBP that links the physical cell 29 microenvironment to a key metabolic pathway.

30

#### 31 Introduction

32 Each tissue has a specific composition of its extracellular matrix (ECM), which is associated to distinctive physical and mechanical properties. These mechanical properties are important for tissue 33 structure, but also control cell function in physiology and disease<sup>1,2</sup>. Cells sense the mechanical 34 35 properties of the ECM through integrin receptors, and measure them by adjusting the contractility of 36 their F-actin cytoskeleton: contractility is maximal when cells are free to spread on stiff ECM substrata, 37 while it is progressively decreased on a soft ECM or in conditions of limited spreading. This is 38 sufficient to control the switch between proliferation, differentiation and death in very diverse cell types, by regulating intracellular signaling pathways such as YAP/TAZ<sup>3,4</sup> and SRF<sup>5,6</sup>. In support of this 39 40 model, inhibition of key players that maintain F-actin contractility including the small GTPase RHO, 41 ROCK (RHO kinase), MLCK (myosin light chain kinase) and non-muscle myosin (NMII) induce similar responses to a soft ECM<sup>1</sup>. Yet, what other general aspects of cell biology are regulated by 42 43 mechanical cues, and through which mechanism(s), remain largely unexplored. This is especially true 44 in the case of metabolism, a fundamental engine that is constantly remodeled to match the energetic 45 and biosynthetic requirements of the cell, whose connections to mechanical cues are only starting to emerge<sup>7,8</sup>. 46

47

## 48 Actomyosin regulates lipid metabolism

To test in an unbiased manner the possibility that actomyosin contractility regulates metabolism we compared by global metabolomics cells in conditions of high contractility (i.e. plated on plastics) with cells in conditions of low contractility, by inhibiting ROCK and MLCK. Analysis of steady-state levels of multiple metabolites indicated clear differences between controls and treated cells (Fig. **1a** and Supplementary Fig. **1a-e**); the most significant and quantitative changes, which were maintained or increased between 6 and 24 hours, were the accumulation of several lipid molecules (Supplementary Fig. **1e** and Ref.<sup>9</sup>).

56 We validated this initial observation with a targeted lipidomic analysis at 24 hours, which 57 confirmed accumulation of triglycerides, diacylglycerols, lyso-phospholipids and ceramides, while many other lipid species remained overall unchanged (Fig. 1b-d, Supplementary Fig. 1f-h and Ref.<sup>9</sup>). 58 59 This was accompanied by increased free and total fatty acids and cholesterol in cell extracts (Fig. 1e,f), 60 and by a corresponding accumulation of cholesterol and neutral lipids in fixed cells (by Filipin and Oil-Red-O stains, respectively – Fig. 1g, Supplementary Fig. 1i-k). Such accumulation was visible after 6 61 62 hours of treatment, and sustained up to 48 hours (Supplementary Fig. 11). A similar effect was observed 63 by replacing Y27632 with Fasudil, an alternative ROCK inhibitor, or by using Y27632 or ML7 64 inhibitors alone (Fig. 1g). Accumulation of lipids was mainly due to increased synthesis, because it was 65 impaired in cells where rate-limiting enzymes of cholesterol and fatty-acid synthesis were inhibited by 66 Cerivastatin or TOFA (Fig. 1g). Finally, lipid accumulation was a general response to ECM mechanical 67 cues and actomyosin contractility because expression of the RHO inhibitor C3, treatment of cells with 68 the NMII small-molecule inhibitor Blebbistatin, or seeding cells on a soft vs. stiff fibronectin-coated 69 polyacrylamide hydrogels induced a coherent accumulation of cholesterol and lipid droplets (Fig. 1h-i). 70 We then extended these findings in multiple cell types including primary, immortalized, and 71 transformed cells, of both epithelial and connective tissue origin, indicating that lipid accumulation is a 72 widespread response to conditions of reduced actomyosin contractility (Fig. 1j,k and Supplementary 73 Fig. **1m,n**).

74

## 75 ECM mechanical cues regulate a genetic program for lipid synthesis

Thinking of potential mechanisms underlying this metabolic shift, we tested an involvement of the Hippo pathway. YAP/TAZ are inhibited by reduced actomyosin contractility<sup>3,4</sup>, but their knockdown did not cause lipid accumulation comparable to ROCK/MLCK inhibition (Supplementary Fig. **2a**). Similarly, stable TAZ-S4A active mutant expression was not sufficient to prevent lipid accumulation upon ROCK/MLCK inhibition (Supplementary Fig. **2b**). LATS1/2 Hippo kinases can be activated by

reduced actomyosin contractility<sup>10</sup>, but genetics indicated that LATS2 inhibits lipid metabolism<sup>11</sup>, 81 82 which was incompatible with our results. This suggested the regulation of an alternative pathway that 83 we sought to identify by performing microarray analysis of MCF10ATk1 cells treated with 84 Y27632+ML7, followed by gene list enrichment analysis. As shown in Fig. 2a,b we found a striking 85 enrichment of signatures related to cholesterol and fatty acid synthesis among the upregulated genes, 86 including many known SREBP1 and SREBP2 (sterol regulatory element binding proteins) targets, pointing to activation of these transcription factors<sup>12,13</sup>. We thus validated activation of SREBP1/2 by a 87 88 luciferase reporter for SREBP transcriptional activity, by qPCR, and in multiple cell lines (Fig. 2c,d 89 and Supplementary Fig. 2d-f). Importantly, we also observed a coherent induction of SREBP target 90 genes in cells cultured on soft hydrogels (Fig. 2e-g), while YAP/TAZ inhibition had no effects on 91 SREBP activity (Supplementary Fig. 2g,h). Of note, among the validated SREBP targets LDLR (low 92 density lipoprotein receptor) expression correlated with increased fatty acid uptake (Supplementary 93 Fig. 2i), and ACSS2 (acyl-CoA synthetase short chain family member 2) with increased usage of acetate for lipid synthesis<sup>14</sup> (Supplementary Fig. 2j). 94

95

#### 96 ECM mechanical cues control lipid synthesis through direct regulation of SREBP1/2 activity

97 SREBP are produced as transmembrane proteins resident in the ER (endoplasmic reticulum) (see 98 model in Supplementary Fig. **3a**): in the presence of sterols and fatty acids, SCAP (SREBP cleavage-99 activating protein) and Insig (insulin-induced gene) proteins bind SREBP and limit their transport to 100 the Golgi apparatus; in absence of lipids, conformational changes in SCAP and Insig enable the 101 quantitative transport of SCAP and SREBP to the Golgi, where SREBP are processed by the S1P (site-102 1 protease) and S2P (site-2 protease) Golgi-resident enzymes. This in turn releases the cytoplasmic 103 portion of SREBP that is free to accumulate into the nucleus to regulate gene transcription<sup>12,13</sup>.

104 Prompted by the observation that mechanical cues regulate SREBP activity, we sought to 105 causally link SREBP activity with the effects of mechanical cues. As shown in Fig. 3a-c and 106 Supplementary Fig. 3b,c knockdown of SREBP1/2 inhibited expression of lipid enzymes and lipid 107 accumulation in response to Y27632+ML7 and to a soft hydrogel. We then probed endogenous 108 SREBP2 localization and observed an early concentration to the Golgi apparatus (2 hours), closely 109 followed by nuclear accumulation (4-6 hours), upon treatment with ROCK/MLCK inhibitors (Fig. 3d and Supplementary Fig. 3d-g). Nuclear accumulation of SREBP2 started to fade at 24 hours and 110 111 became almost undetectable at 48 hours of treatment (Fig. 3d), likely due to accumulation of lipids 112 eventually restraining SREBP activation. Moreover, nuclear accumulation was reversible, since 113 washout of the inhibitors led to the rapid disappearance of nuclear SREBP2 (Fig. 3d). In keeping with a 114 general effect of mechanical cues, nuclear SREBP2 was observed upon transfection of the C3 RHO inhibitor, treatment with Blebbistatin, and on soft hydrogels (Fig. 3d and Supplementary Fig. 3f,g). 115 116 This was associated with accumulation of cleaved SREBP1 and SREBP2 in nuclear extracts (Fig. 3e 117 and Supplementary Fig. **3h**). In line with a direct effect, nuclear accumulation of SREBP2 occurred in 118 absence of protein synthesis (Fig. 3f,g and Supplementary Fig. 3i,j). Finally, ROCK/MLCK inhibitors could not stimulate further LDLR-luciferase in cells engineered to express only a mature form of 119 120 SREBP2 (Fig. 3h), indicating regulation of SREBP2 at the level of cleavage and not of nuclear 121 stability.

122

#### 123 Inhibition of SREBP activity by pathological tissue stiffness

To find evidence that this regulation also occurs in vivo, we queried gene expression data obtained by 124 comparing patient-matched normal skin with keloid scars<sup>15</sup>, a fibroproliferative disorder characterized 125 by increased tissue stiffness and whose expansion is linked to mechanical stress<sup>16,17</sup>. Strikingly, several 126 127 SREBP target genes were consistently and uniformly downregulated in stiffened keloids across all 128 patients, supporting our model (Fig. 3i). Of note, this finding nicely parallels the so-far unexplained decrease in lipids and cholesterol-esters observed in keloids<sup>18</sup>. As a control, we also found upregulation 129 of several YAP/TAZ target genes (Fig. 3i), in line with stiffness-induced YAP/TAZ activity during 130 fibrosis<sup>19,20</sup>. Thus, cytoskeletal tension is a relevant input to regulate SREBP in vitro and in at least one 131 132 human pathological tissue.

133

## 134 ECM mechanical cues regulate SCAP localization and function

135 We next probed the subcellular localization of core SREBP regulators. While Insig1 and S1P remained 136 correctly confined to the ER and the Golgi apparatus, respectively (Supplementary Fig. 4a,b), we 137 observed translocation of SCAP to the Golgi apparatus by plating cells on soft hydrogels and after 138 inhibition of RHO or ROCK/MLCK (Fig. 4a,b and Supplementary Fig. 4c). This was instrumental for 139 the regulation of SREBP by mechanical cues, because both SCAP knockdown and treatment of cells with 25-hydroxycholesterol, a dominant inhibitor of SCAP transport<sup>21</sup>, decreased SREBP activation 140 (Fig. 4c,e and Supplementary Fig. 4d). In line, treating cells with the S1P inhibitor PF429242 also 141 prevented activation of SREBP (Fig. 4d,e). This indicates that actomyosin contractility prevents 142 143 accumulation of SCAP/SREBP to the Golgi apparatus and the exposure of SREBP to Golgi proteases.

#### 145 Lipid synthesis contributes to the beneficial effects of ROCK inhibitors in hPSC

146 To expand the functional implications of these findings we used human Pluripotent Stem Cells (hPSC). These cells require treatment with the Y27632 ROCK inhibitor to survive single-cell dissociation, 147 while they thrive without inhibitor once they have attached to the substrate<sup>22,23</sup>. We thus tested the idea 148 149 that Y27632 might promote survival of hPSC by enhancing lipid synthesis. We first confirmed that 150 Y27632 induces lipid accumulation also in these cells (Supplementary Fig. 4e). We then challenged 151 Y27632-induced survival of hPSC seeded as single cells by using very low doses of lipid synthesis 152 inhibitors (Cerivastatin and TOFA), and found that hPSC did not survive (Fig. 4f, single cells); the 153 same dose of inhibitors was instead inconsequential for cell survival of already-established hPSC 154 colonies, when Y27632 is not required (Fig. 4f, colonies). In line, both treatment of cells with 25-155 hydroxycholesterol and transfection of SREBP1/2 siRNAs impaired Y27632-induced single-cell 156 survival (Fig. 4g,h). These results suggest that isolated hPSC are highly dependent on lipid synthesis, 157 and that ROCK inhibition promotes their survival, at least in part, by sustaining SREBP activity.

158

#### 159 Uncoupling actomyosin contractility from intracellular cholesterol trafficking

160 One possibility to explain our findings is that reduced actomyosin contractility leads to reduced levels 161 of sterols at the ER because of decreased transport of extracellular cholesterol from the endosome/lysosome to the ER by the NPC1 transporter<sup>12,13</sup>. We excluded this scenario based on the 162 163 following observations: (i) cholesterol accumulation in response to Y27632+ML7 was decreased in 164 cells with inhibited synthesis or with SREBP1/2 knockdown (see above), indicating it is a secondary 165 effect; (ii) cholesterol accumulation occurred after SREBP activation, and with a delayed kinetics 166 compared to inhibition of the NPC1 transporter with U18666A (Supplementary Fig. 5a); (iii) while 167 U18666A induced accumulation of cholesterol in LAMP2-encircled lysosomal structures, as expected, 168 only few Y27632+ML7-induced cholesterol dots were positive for LAMP2 (Supplementary Fig. 5b); 169 (iv) treatment with Y27632+ML7, at difference with U18666A or with serum (and, thus, LDL-170 cholesterol) deprivation, did not cause concentration of the ER cholesterol-sensing protein OSBP to the Golgi apparatus at early time-points<sup>24,25</sup> (Supplementary Fig. 5c). 171

172

### 173 Linking actomyosin contractility to the Lipin-1/ARF1 SREBP-regulatory axis

Looking for alternative mechanisms, we reasoned that among the known SREBP-regulatory inputs, two act independently of sterol levels: ARF1 and Lipin-1. The ARF1 (ADP ribosylation factor 1) small G protein regulates Golgi dynamics<sup>26,27</sup>, and inhibits SREBP<sup>28-30</sup>. The precise mechanism remained 177 incompletely understood, because Walker and colleagues showed that ARF1 prevents S1P from 178 shuttling to the ER, while Nakayama and colleagues showed that the ARF1 effector COPI prevents 179 accumulation of SCAP/SREBP to the Golgi. Lipin-1 is a phosphatase that converts phosphatidates into diacylglycerols at cytoplasmic membranes<sup>31</sup>, and also an inhibitor of SREBP activity<sup>29,32</sup>. Interestingly, 180 ARF1 recruitment to the Golgi apparatus and formation of COPI-coated vesicles requires 181 182 diacylglycerols<sup>33-36</sup>, such that inhibition of Lipin-1 activity can cause ARF1 dissociation from Golgi membranes and ARF1 inhibition<sup>29,35</sup>. This suggested us that reduced actomyosin contractility might 183 184 induce SREBP activity by inhibiting Lipin-1/ARF1 (see model in Supplementary Fig. 5d).

185 We first verified that inhibition of Lipin-1, ARF1 or COPI induce SREBP activation, SCAP accumulation at the Golgi apparatus and lipid accumulation in our systems (Fig. 5a-f and 186 187 Supplementary Fig. 5e). We then indirectly gauged Lipin-1 activity by monitoring its association with microsomes<sup>37,38</sup> or by monitoring Golgi membrane diacylglycerol (DG) content with the DG-binding 188 domain of PKD1 (GFP-PKD-KD)<sup>35,39,40</sup>, and found that inhibition of ROCK/MLCK rapidly caused 189 190 Lipin-1 dissociation from microsomes (Fig. 5g) and decreased GFP-PKD-KD co-localization with the 191 Golgi apparatus (Fig. 5h). ROCK/MLCK inhibition also decreased ARF1 activity (Fig. 5i) and ARF1 192 recruitment to the Golgi apparatus (Fig. 5j). Moreover, both Lipin-1 and ROCK/MLCK inhibition 193 induce similar remodeling of Golgi morphology at late time-points (Supplementary Fig. 5f,g), a phenotype previously observed in cells depleted of GBF1/ARF1<sup>28</sup>. We did not observe a general 194 195 redistribution of a fluorescent KDEL reporter (Supplementary Fig. 5h), indicating overall intact 196 transports between ER and Golgi. Collectively, our data indicate that mechanical cues control Lipin-1 197 activity, causing altered ARF1-dependent trafficking of SCAP/SREBP between the Golgi and the ER.

198

# 199 Actomyosin contractility controls SREBP through Lipin-1, but independently from 200 AMPK/mTOR

201 We then explored how Lipin-1 is regulated. Lipin-1 activity and association to cytoplasmic membranes can be inhibited by phosphorylation<sup>32,37,38</sup>. We checked Lipin-1 overall phosphorylation levels, but we 202 203 did not observe major changes of the Lipin-1 migratory pattern (Fig. 6a). We also monitored Lipin-1 204 subcellular localization by immunofluorescence, and found that reduced contractility partially shifted 205 FLAG-Lipin-1 towards the nucleus (Fig. 6b,c). Nuclear Lipin-1 has been associated with inactivation of SREBP<sup>32</sup>; since we observed a partial nuclear accumulation of Lipin-1 in conditions of active 206 207 SREBP, we then wondered what pool of Lipin-1 was relevant in our cells. For this we compared wild-208 type Lipin-1 (WT) with a nuclear phospho-mutant (17S/A) and with Lipin-1 isoforms that we designed 209 to constitutively associate with ER/Golgi membranes (MB-Lipin-1 and MB\*-Lipin-1 - see Fig. 6c), and 210 used these to challenge the effects of reduced contractility. While the WT and 17S/A mutant were 211 inactive, expression of membrane-associated Lipin-1 counteracted SREBP activity (Fig. 6d,e) and lipid accumulation (Fig. 6f). Also the SUMOvlation<sup>41</sup> and acetvlation<sup>42</sup> Lipin-1 mutants were inactive in the 212 213 same assay (Supplementary Fig. 6a). Collectively, these results indicate that reduced contractility 214 inhibits the affinity of Lipin-1 for ER/Golgi membranes, leading to nuclear localization of Lipin-1 as secondary effect. This occurs independently from mTOR, a known Lipin-1 regulatory input 215 216 (Supplementary Fig. 6b,c), and also from AMPK, a main metabolic regulator (Supplementary Fig. 217 6d.e).

218

## 219 The Golgi apparatus responds to extracellular and intracellular forces

220 We finally sought to obtain some insight into how extracellular mechanical cues influence signaling at the Golgi apparatus. Transmission of forces from the ECM entail activation of signaling molecules at 221 focal adhesions<sup>1</sup> but also occur in a direct fashion, for example by stretching the plasma membrane, or 222 owing to anchoring of stress fibers to the nuclear lamina<sup>43,44</sup>. Whether the Golgi apparatus might 223 224 respond in a similar fashion has not been explored, but Golgi cisternae are embedded in a complex cvtoskeletal network<sup>45,46</sup>, and the Golgi microenvironment is endowed of an intrinsic mechanical 225 rigidity which depends on ROCK/MLCK<sup>47</sup>. To measure the response of Golgi rigidity to external 226 227 physical cues we plated cells on small fibronectin-coated micropatterns, to which cells respond by decreasing actomyosin contractility<sup>48</sup>, and by accumulating SCAP to the Golgi apparatus (Fig. **7a**). We 228 229 then measured Golgi rheology by pushing on the Golgi apparatus a cytoplasmic bead immobilized in a 230 laser optical trap (see methods and Supplementary Fig. 7a). Analysis of the averaged relaxation curves 231 (Fig. 7b and Supplementary Fig. 7b) indicated a lower rigidity of the Golgi apparatus in micropatterned 232 cells, apparent from reduction of the bead step amplitude, the rigidity index, and the frequency of bead 233 ejection (Fig. 7c). As a control, moving the bead away from the Golgi showed that the overall 234 cytoplasmic stiffness is not altered (Supplementary Fig. 7c). This experiment indicates that Golgi 235 stiffness is coupled, directly or indirectly, to the mechanical properties of the ECM. Strikingly, with this set-up we also observed that direct application of force to the Golgi apparatus was sufficient to 236 237 induce recruitment of the GFP-PKD-KD reporter (Fig. 7d,e), in line with higher Lipin-1 activity in 238 cells developing higher contractile forces (see above).

- 239
- 240 **Discussion**

241 Seminal work demonstrating that cells sense ECM mechanical cues set the array of bona-fide 242 mechanoregulated phenotypes in vitro. Yet, what other general cell phenotypes are regulated by 243 mechanical cues remains largely unexplored. Here we focused on cell metabolism and identified 244 neutral lipid and cholesterol synthesis as a general response to reduced actomyosin contractility and to a soft ECM microenvironment. We propose that decreased extracellular forces reverberate on Golgi 245 246 rheology and inactivate Lipin-1, causing alteration of diacylglycerol at the Golgi apparatus, reduced 247 recruitment of ARF1, and ultimately leading to activation of SREBP1/2 transcription factors. As such, 248 our data provide a missing upstream input for the Lipin-1 and ARF1 SREBP-regulatory axis, whose players were previously identified in C.  $elegans^{29}$ , and validates the idea that continuous shuttling of 249 SCAP/SREBP from the Golgi to the ER is a significant mechanism limiting their activation<sup>30</sup>. These 250 251 findings led us to revisit the requirement of isolated human pluripotent stem cells for ROCK inhibition, that we found linked to the ability to sustain SREBP activity and lipid synthesis. We speculate this 252 might underlie the beneficial effect of ROCK inhibition observed for isolation of other primary stem-253 cell populations<sup>49-51</sup>. These findings also indicate that physiological or pathological conditions leading 254 255 to altered tissue stiffness may impact SREBP activity and lipid metabolism; strikingly, we could obtain 256 a proof-of-principle for this in human keloid scars, providing a plausible explanation for reduced triglycerides and cholesteryl-esters<sup>18</sup>. Thus, we here identify an unexpected and widespread 257 258 mechanoresponsive phenotype, and its main underlying mechanism. Our findings raise interesting 259 questions on how Lipin-1 is regulated in this context; we speculate that Lipin-1 macromolecular complexes observed on supported lipid bilayers in vitro<sup>52</sup> are endowed of curvature-sensing ability, 260 261 which might link Lipin-1 activity to the rheology of Golgi membranes and the cytoskeleton. In future, 262 it will be interesting to test whether ECM mechanical cues affect other functions of the Golgi, of Lipin-263 1 signaling and of ARF1, and how these impact the response of normal and diseased tissues to 264 mechanical cues.

265

#### 266 **References**

- 1. Iskratsch, T., Wolfenson, H. & Sheetz, M. P. Appreciating force and shape—the rise of mechanotransduction in cell biology. *Nat. Rev. Mol. Cell Biol.* **15**, 825–833 (2014).
- 269 2. LeGoff, L. & Lecuit, T. Mechanical Forces and Growth in Animal Tissues. *Cold Spring Harbor* 270 *Perspectives in Biology* 8, a019232 (2015).
- 271 3. Dupont, S. *et al.* Role of YAP/TAZ in mechanotransduction. *Nature* **474**, 179–183 (2011).
- 4. Dupont, S. Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction. *Exp. Cell Res.* 343, 42–53 (2016).
- 5. Miralles, F., Posern, G., Zaromytidou, A.-I. & Treisman, R. Actin dynamics control SRF activity
  by regulation of its coactivator MAL. *Cell* 113, 329–342 (2003).

- Janmey, P. A., Wells, R. G., Assoian, R. K. & McCulloch, C. A. From tissue mechanics to transcription factors. *Differentiation* 86, 112–120 (2013).
- Coloff, J. L. *et al.* Differential Glutamate Metabolism in Proliferating and Quiescent Mammary
   Epithelial Cells. *Cell Metabolism* 23, 867–880 (2016).
- Bays, J. L., Campbell, H. K., Heidema, C., Sebbagh, M. & DeMali, K. A. Linking E-cadherin
   mechanotransduction to cell metabolism through force-mediated activation of AMPK. *Nat. Cell Biol.* 19, 724–731 (2017).
- 283
  9. Romani, P. *et al.* Metabolomics and Lipidomics analyses of MCF10ATk1 cells treated with
  284 ROCK/MLCK inhibitors. *Figshare database* (2018). doi:10.6084/m9.figshare.7338764
- 285 10. Zhao, B. *et al.* Cell detachment activates the Hippo pathway via cytoskeleton reorganization to
   286 induce anoikis. *Genes Dev.* 26, 54–68 (2012).
- Aylon, Y. *et al.* The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic
  cholesterol accumulation. *Genes Dev.* (2016). doi:10.1101/gad.274167.115
- Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology divergent pathophysiology. *Nat Rev Endocrinol* (2017). doi:10.1038/nrendo.2017.91
- Brown, M. S., Radhakrishnan, A. & Goldstein, J. L. Retrospective on Cholesterol Homeostasis:
  The Central Role of Scap. *Annu. Rev. Biochem.* 87, annurev–biochem–062917–011852 (2017).
- 293 14. Comerford, S. A. et al. Acetate Dependence of Tumors. Cell 159, 1591–1602 (2014).
- Hsu, C.-K. *et al.* Caveolin-1 Controls Hyperresponsiveness to Mechanical Stimuli and
   Fibrogenesis-Associated RUNX2 Activation in Keloid Fibroblasts. *J. Invest. Dermatol.* (2017).
   doi:10.1016/j.jid.2017.05.041
- 16. Ogawa, R. Mechanobiology of scarring. *Wound Repair Regen* **19 Suppl 1**, s2–9 (2011).
- Aya, R. *et al.* The Shear Wave Velocity on Elastography Correlates with the Clinical Symptoms
  and Histopathological Features of Keloids. *Plastic and Reconstructive Surgery Global Open* 3,
  e464 (2015).
- Tachi, M. & Iwamori, M. Mass spectrometric characterization of cholesterol esters and wax
   esters in epidermis of fetal, adult and keloidal human skin. *Experimental Dermatology* 17, 318–323 (2008).
- Calvo, F. *et al.* Mechanotransduction and YAP-dependent matrix remodelling is required for the
   generation and maintenance of cancer-associated fibroblasts. *Nat. Cell Biol.* 15, 637–646 (2013).
- Liu, F. *et al.* Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.
   *Am. J. Physiol. Lung Cell Mol. Physiol.* 308, L344–57 (2015).
- Sun, L.-P., Seemann, J., Goldstein, J. L. & Brown, M. S. Sterol-regulated transport of SREBPs
   from endoplasmic reticulum to Golgi: Insig renders sorting signal in Scap inaccessible to COPII
   proteins. *Proc. Natl. Acad. Sci. U.S.A.* 104, 6519–6526 (2007).
- Watanabe, K. *et al.* A ROCK inhibitor permits survival of dissociated human embryonic stem
  cells. *Nat Biotechnol* 25, 681–686 (2007).
- 313 23. Ohgushi, M. *et al.* Molecular pathway and cell state responsible for dissociation-induced
  apoptosis in human pluripotent stem cells. *Cell Stem Cell* 7, 225–239 (2010).
- Storey, M. K., Byers, D. M., Cook, H. W. & Ridgway, N. D. Cholesterol regulates oxysterol
  binding protein (OSBP) phosphorylation and Golgi localization in Chinese hamster ovary cells:
  correlation with stimulation of sphingomyelin synthesis by 25-hydroxycholesterol. *Biochem. J.* **336 (Pt 1)**, 247–256 (1998).
- 319 25. Mohammadi, A. *et al.* Golgi localization and phosphorylation of oxysterol binding protein in
  320 Niemann-Pick C and U18666A-treated cells. *J. Lipid Res.* 42, 1062–1071 (2001).
- 321 26. De Matteis, M. A. & Godi, A. Protein-lipid interactions in membrane trafficking at the Golgi
  322 complex. *Biochim. Biophys. Acta* 1666, 264–274 (2004).
- 323 27. D'Souza-Schorey, C. & Chavrier, P. ARF proteins: roles in membrane traffic and beyond. Nat.

- 324 *Rev. Mol. Cell Biol.* **7**, 347–358 (2006).
- 325 28. Walker, A. K. *et al.* A conserved SREBP-1/phosphatidylcholine feedback circuit regulates
  326 lipogenesis in metazoans. *Cell* 147, 840–852 (2011).
- 327 29. Smulan, L. J. *et al.* Cholesterol-Independent SREBP-1 Maturation Is Linked to ARF1
  328 Inactivation. *CellReports* 16, 9–18 (2016).
- 30. Takashima, K. *et al.* COPI-mediated retrieval of SCAP is crucial for regulating lipogenesis
  under basal and sterol-deficient conditions. *J. Cell. Sci.* 128, 2805–2815 (2015).
- 31. Zhang, P. & Reue, K. Lipin proteins and glycerolipid metabolism: Roles at the ER membrane
  and beyond. *Biochim. Biophys. Acta* 1859, 1583–1595 (2017).
- 333 32. Peterson, T. R. *et al.* mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP
  334 Pathway. *Cell* 146, 408–420 (2011).
- 33. Fernández-Ulibarri, I. *et al.* Diacylglycerol is required for the formation of COPI vesicles in the
  Golgi-to-ER transport pathway. *Mol. Biol. Cell* 18, 3250–3263 (2007).
- 337 34. Asp, L. *et al.* Early stages of Golgi vesicle and tubule formation require diacylglycerol. *Mol.*338 *Biol. Cell* 20, 780–790 (2009).
- 339 35. Baron, C. L. & Malhotra, V. Role of diacylglycerol in PKD recruitment to the TGN and protein
  340 transport to the plasma membrane. *Science (New York, N.Y.)* 295, 325–328 (2002).
- 341 36. Antonny, B., Huber, I., Paris, S., Chabre, M. & Cassel, D. Activation of ADP-ribosylation factor
  342 1 GTPase-activating protein by phosphatidylcholine-derived diacylglycerols. *Journal of*343 *Biological Chemistry* 272, 30848–30851 (1997).
- 344 37. Harris, T. E. *et al.* Insulin controls subcellular localization and multisite phosphorylation of the
  345 phosphatidic acid phosphatase, lipin 1. *Journal of Biological Chemistry* 282, 277–286 (2007).
- 346 38. Péterfy, M., Harris, T. E., Fujita, N. & Reue, K. Insulin-stimulated interaction with 14-3-3
  347 promotes cytoplasmic localization of lipin-1 in adipocytes. *J. Biol. Chem.* 285, 3857–3864
  348 (2010).
- 349 39. Hausser, A. *et al.* Protein kinase D regulates vesicular transport by phosphorylating and
  activating phosphatidylinositol-4 kinase IIIbeta at the Golgi complex. *Nat. Cell Biol.* 7, 880–886
  (2005).
- Villani, M. *et al.* Sphingomyelin synthases regulate production of diacylglycerol at the Golgi.
   *Biochem. J.* 414, 31–41 (2008).
- 41. Liu, G.-H. & Gerace, L. Sumoylation regulates nuclear localization of lipin-1alpha in neuronal
   cells. *PLoS ONE* 4, e7031 (2009).
- 42. Li, T. Y. *et al.* Tip60-mediated lipin 1 acetylation and ER translocation determine triacylglycerol
   synthesis rate. *Nat Comms* 9, 1916 (2018).
- 43. Isermann, P. & Lammerding, J. Nuclear Mechanics and Mechanotransduction in Health and
   Disease. *Current Biology* 23, R1113–R1121 (2013).
- 44. Coste, B. *et al.* Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. *Science (New York, N.Y.)* 330, 55–60 (2010).
- 45. Egea, G., Lázaro-Diéguez, F. & Vilella, M. Actin dynamics at the Golgi complex in mammalian cells. *Curr. Opin. Cell Biol.* 18, 168–178 (2006).
- Gurel, P. S., Hatch, A. L. & Higgs, H. N. Connecting the Cytoskeleton to the Endoplasmic
  Reticulum and Golgi. *Current Biology* 24, R660–R672 (2014).
- Guet, D. *et al.* Mechanical role of actin dynamics in the rheology of the Golgi complex and in
  Golgi-associated trafficking events. *Current biology* : *CB* 24, 1700–1711 (2014).
- 48. Fu, J. *et al.* Mechanical regulation of cell function with geometrically modulated elastomeric
  substrates. *Nat. Methods* 7, 733–736 (2010).
- 49. Sato, T. & Clevers, H. Growing self-organizing mini-guts from a single intestinal stem cell:
  mechanism and applications. *Science (New York, N.Y.)* 340, 1190–1194 (2013).

- McFarlane, M. R. *et al.* Scap is required for sterol synthesis and crypt growth in intestinal
  mucosa. *J. Lipid Res.* 56, 1560–1571 (2015).
- Katsuda, T. *et al.* Conversion of Terminally Committed Hepatocytes to Culturable Bipotent
   Progenitor Cells with Regenerative Capacity. *Cell Stem Cell* 20, 41–55 (2017).
- 52. Creutz, C. E., Eaton, J. M. & Harris, T. E. Assembly of high molecular weight complexes of
  lipin on a supported lipid bilayer observed by atomic force microscopy. *Biochemistry* 52, 5092–
  5102 (2013).
- Watson, R. T. & Pessin, J. E. Transmembrane domain length determines intracellular membrane
  compartment localization of syntaxins 3, 4, and 5. *Am. J. Physiol., Cell Physiol.* 281, C215–23
  (2001).
- Misumi, Y., Sohda, M., Tashiro, A., Sato, H. & Ikehara, Y. An essential cytoplasmic domain for
  the Golgi localization of coiled-coil proteins with a COOH-terminal membrane anchor. *Journal of Biological Chemistry* 276, 6867–6873 (2001).
- 55. Enzo, E. *et al.* Aerobic glycolysis tunes YAP/TAZ transcriptional activity. *EMBO J.* 34, 1349–
  1370 (2015).
- 387 56. Aragona, M. *et al.* A mechanical checkpoint controls multicellular growth through YAP/TAZ
  388 regulation by actin-processing factors. *Cell* 154, 1047–1059 (2013).
- Santinon, G. *et al.* dNTP metabolism links mechanical cues and YAP/TAZ to cell growth and
   oncogene-induced senescence. *EMBO J.* 37, e97780 (2018).
- 391 58. Irizarry, R. A. *et al.* Exploration, normalization, and summaries of high density oligonucleotide
  392 array probe level data. *Biostatistics* 4, 249–264 (2003).
- Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the
  ionizing radiation response. *Proc. Natl. Acad. Sci. U.S.A.* 98, 5116–5121 (2001).
- Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016
  update. *Nucleic Acids Res.* 44, W90–7 (2016).
- Horton, J. D. *et al.* Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. *Proc. Natl. Acad. Sci. U.S.A.* 100, 12027–12032 (2003).
- 40062.Porstmann, T. *et al.* PKB/Akt induces transcription of enzymes involved in cholesterol and fatty401acid biosynthesis via activation of SREBP. *Oncogene* 24, 6465–6481 (2005).
- 402 63. Mandal, K., Asnacios, A., Goud, B. & Manneville, J.-B. Mapping intracellular mechanics on
  403 micropatterned substrates. *Proceedings of the National Academy of Sciences* 113, E7159–E7168
  404 (2016).
- 405 406

# 407 Acknowledgements

- 408 We are grateful to Y. Chen, K. Mori, G. DelSal, B. Viollet and H. Louvel, E. Greotti, A. DeMatteis and R. Venditti, A. Hausser, R. Rizzuto and D. Vecellio Reane, L. Scorrano and L. Pernas, C. Cheng, E. 409 410 Melloni, M. Pende and R. Talha, R. Ogawa, J. Goldstein P. Espenshade and W. Shao for advice and 411 materials. We are indebted to S. Giulitti for generous help with hydrogels, to M. Pellegrini and I. Zorzan for help with hPSC cultures, to G. Martello and M. Montagner for thoughtful discussion. This 412 work was supported by AIRC IG-15307, WCR 15-1192, CARIPARO Eccellenza 2017 and University 413 of Padua BIRD grants to SD, AIRC 'Hard ROCK Café Fellowship to GS, UPMC 'Interface pour le 414 Vivant' doctoral program to SM, AIRC Special Program Molecular Clinical Oncology '5 per mille' 415 416 10016 to SB.
- 417
- 418 **Author contributions**

- 419 PR and IB performed experiments and analyzed data with help from GS and AP; MA and SP and NM
- 420 performed metabolic measurements and advised on the interpretation of metabolic data; SM and JBM
- 421 performed Golgi micromanipulations; MF and SB performed bioinformatics analyses; SD and PR
- 422 planned experiments; SD coordinated and supervised the project, and wrote the paper.423

## 424 **Competing Interests**

- 425 The authors declare no competing or financial interests.
- 426

# 427 Figure legends

428

# 429 Figure 1. Actomyosin contractility and ECM mechanical cues regulate lipid synthesis.

a, Principal component analysis of metabolites altered by global metabolomics in MCF10ATk1 human 430 431 mammary epithelial cells treated for 6 or 24 hours with 20uM Y27632 ROCK inhibitor and 20uM ML7 MLCK inhibitor to inhibit actomyosin contractility (hereafter YM, n=6 biologically independent 432 433 samples), as compared to vehicle (DMSO, n=4 biologically independent samples). **b**, Volcano plot of 434 lipid molecules altered in MCF10ATk1 cells treated for 24 hours with YM, as measured by targeted 435 lipidomics. n=5 biologically independent samples per condition. TG, triacylglycerols; DG, 436 diacylglycerols; LysoPC, lyso-phosphatidylcholines; Cer, ceramides. c,d, TG (c) and DG (d) levels in 437 MCF10ATk1 cells treated with YM for 24 hours, as measured by mass spectrometry. Only the five 438 most abundant species are shown. e.f. Fatty acids (e, n=5 biologically independent samples per 439 condition) and cholesterol (f, n=9 biologically independent samples per condition) in MCF10ATk1 440 cells treated with YM, as assayed by standard colorimetric assays. g, Filipin staining for cholesterol and Oil-Red-O staining (ORO) for neutral lipids in MCF10ATk1 cells treated with YM or FM 441 442 (Fasudil+ML7). Inhibition of cholesterol and fatty acid synthesis with 10µM Cerivastatin (Ceri) or with 443 15µM TOFA prevents accumulation. Here and through all figures, image acquisition settings were the 444 same between controls and experimental samples. Scale bar 5um. h. Accumulation of cholesterol and neutral lipids in MCF10ATk1 cells upon inhibition of RHO (C3 transferase transfection), non-muscle 445 myosin II (20µM Blebbistatin) or by plating cells on soft (E≈0.5kPa) fibronectin-coated 446 polyacrylamide hydrogels, compared to stiff (E≈15kPa) hydrogels. Scale bar 5µm, i, Transmission 447 electron microscope pictures of MCF10ATk1 cells plated on stiff or soft hydrogel, with apparent lipid 448 449 droplets (LD) and part of the nucleus (N). Scale bar 1µm. j,k, non-transformed human RPE1 (j) and primary mouse 3T3L1 (k) cells plated on stiff or soft hydrogels. Scale bar 5µm. The images in panels 450 451 g-k are representative of at least two independent experiments with similar results; quantifications and 452 n are provided in Supplementary Table 2. Data are mean and single points; unpaired two-tailed 453 Student's t-tests.

## 454

# 455 Figure 2. ECM mechanical cues regulate SREBP1/2 target genes.

**a.** Gene list enrichment analysis on probes significantly upregulated (mean fold>1.3 P<0.05) in 456 457 microarrays of MCF10ATk1 cells treated with DMSO or Y27632+ML7 (YM) for 6 hours. The graphs display the 10 most significantly overrepresented gene sets for each of the indicated databases, 458 459 analyzed with Enrichr and ranked according to combined score (x axis). Gene sets related to 460 cholesterol, lipids and SREBP are highlighted in orange. **b**, Heatmap of SREBP target genes in microarrays of MCF10ATk1 cells treated as in **a**. Each column is an independent biological sample 461 462 (n=3 for each condition); each line corresponds to a single gene probe indicated on the right. Blue and 463 yellow extremes correspond to raw Z-scores of -2 and +2, respectively. c, LDLR-luciferase reporter assay for SREBP activity in MDA231 cells treated with YM or Fasudil+ML7 (FM). Mean expression 464 465 in controls was set to 1, and other samples are relative to this ( $n \ge 6$  independent biological samples per 466 condition; unpaired Mann-Whitney tests). d, qPCR for established SREBP targets in RPE1 cells treated for 6 or 24 hours with DMSO, YM or FM ( $n \ge 4$  independent biological samples per condition; multiple 467 unpaired two-tailed Student's t-tests). e-g, qPCR for established SREBP targets in MCF10ATk1 (e), 468 469 RPE1 (f) or 3T3L1 (g) cells plated on stiff ( $E\approx 15$ kPa) or soft ( $E\approx 0.5$ kPa) ECM-coated hydrogels for 24 470 hours ( $n\geq4$  independent biological samples per condition; multiple unpaired two-tailed Student's t-471 tests). In **d-g** data are relative to *GAPDH* levels; mean expression in controls (DMSO or stiff) were set 472 to 1, and all other samples are relative to this. Data are mean and single points.

474 Figure 3. ECM mechanical cues regulate lipid synthesis by controlling SREBP1/2 activation. 475 a, qPCR analysis in MCF10ATk1 cells 48 hours after transfection with control siRNA (siCo.) or four 476 independent mixes of siRNAs targeting *SREBF1* and *SREBF2* mRNAs (siSREBP A to D), **b.** aPCR. 477 analysis of established SREBP1/2 targets in MCF10ATk1 transfected as in a and treated with DMSO 478 or YM for 24 hours. In **a** and **b** mRNA expression data are relative to GAPDH levels: mean expression 479 levels in controls was set to 1, and all other samples are expressed relative to this ( $n\geq4$  independent biological samples per condition; unpaired Mann-Whitney tests). **c.** Cholesterol accumulation in 480 MCF10ATk1 cells transfected with SREBP1/2 siRNA (siSREBP mixes A and B) and plated on soft 481 hydrogels. Scale bar 5µm. Quantification and n is provided in Supplementary Table 2. d. 482 483 Immunofluorescence for endogenous SREBP2 in MCF10ATk1 cells with inhibited ROCK/MLCK (YM), RHO (C3 plasmid transfection), MyosinII (Blebbistatin 10µM), or plated on soft hydrogels for 6 484 hours. Cell contour in the YM 2h panel (dotted line) helps visualizing SREBP2 concentration at the 485 Golgi apparatus. Scale bar 10µm. n>50 cells per condition. e, Western blotting for the mature form of 486 487 endogenous SREBP1 and SREBP2 in MCF10ATk1 cells treated 4 hours with YM or FM. TEAD1 is a 488 loading control for nuclear extracts. See also Supplementary Fig. 8. f, Immunofluorescence for 489 endogenous SREBP2 in MCF10ATk1 cells treated 4 hours with YM in the presence of 100µg/ml 490 cycloheximide (CHX). Scale bar 10µm. n>50 cells per condition. g. Western blotting on total extracts of MCF10ATk1 cells untreated (-), treated for 3 hours with 2µg/ml puromycin alone (puro) or with 491 puromycin and 100µg/ml cycloheximide (CHX). Incorporation of the puromycin aminoacid analog 492 493 into nascent proteins is used as control for efficient inhibition of protein synthesis. See also 494 Supplementary Fig. 8. h, LDLR-luciferase in MDA231 cells. YM and FM activate endogenous 495 SREBP, but have no additive effects in cells depleted of SREBP1/2 (siSREBP) and expressing a 496 siRNA-insensitive, cleaved mature SREBP2 cDNA (caSREBP2). Mean expression in controls was set 497 to 1, and other samples are relative to this ( $n \ge 4$  independent biological samples per condition; unpaired Mann-Whitney tests). i, Heatmap of SREBP and YAP target levels in n=7 patient-matched soft normal 498 499 skin vs. stiff keloid tissue. Each column represents -log2(keloid/skin) values for a single patient; each 500 line is a single gene probe; genes ranked according to expression in patient #1. Selected gene names are 501 indicated on the right; only the 60 most up- or downregulated genes (P<0.05) are included. All n values are pooled between independent experiments. The images in **c-g** are representative of at least two 502 503 independent experiments with similar results. Data are mean and single points. 504

# 505 Figure 4. ECM mechanical cues regulate SCAP accumulation to the Golgi apparatus.

506 a, Co-localization of transfected MYC-tagged SCAP with a Golgi marker (GM130) in MCF10ATk1 cells cultured 6 hours on soft hydrogels (E≈0.5kPa), treated 6 hours with Y27632+ML7 (YM) or 507 transfected with the C3 RHO inhibitor. Scale bar 10µm. n>50 cells per condition. **b**, Co-localization of 508 509 transfected MYC-SCAP with a Golgi marker (GFP-Rab6) in RPE1 cells treated 6 hours with YM. 510 Scale bar 10µm. n>50 cells per condition. c, LDLR-luciferase in MDA231 cells transfected with control siRNA (siCo.), with two independent SCAP siRNA (siSCAP A and B), or treated with 30µM 511 25-hvdroxycholesterol (25OHC). d, LDLR-luciferase in MDA231 cells treated with the site-1 protease 512 (S1P) inhibitor PF429242 (10µM). e, LDLR-luciferase in MDA231 cells transfected the C3 RHO 513 inhibitor and treated as in c and d. In panels c-e, n>4 independent biological samples per condition; 514 mean expression in controls were set to 1, and all other samples are relative to this; data are mean and 515 single points; unpaired Mann-Whitney tests. f, Human Pluripotent Stem Cells (hPSC) were dissociated 516 517 and plated as single cells in the absence (DMSO) or presence of 10µM Y27632, without or with titrated doses of Cerivastatin (Ceri 25nM) and TOFA (75nM) for 24 hours, released in medium without 518 519 inhibitors for 4 days, and stained for alkaline phosphatase to visualize self-renewing colonies. Lower 520 panels: similar treatment on already-established colonies. Higher doses of Ceri/TOFA (10µM and

521  $15\mu$ M) inhibit also established colonies. **g**, hPSC plated as in **f** and treated with 1,25 $\mu$ M 25-522 hydroxycholesterol. **h**, hPSC transfected with the indicated siRNAs and plated as single cells. The 523 images in **f-h** are representative of at least two independent experiments with similar results; 524 quantifications and n are provided in Supplementary Table 2. All n values are pooled between 525 independent experiments.

526

# 527 Figure 5. ECM mechanical cues regulate Lipin-1/ARF1 signaling.

528 **a.b.** qPCR for SREBP target genes in MCF10ATk1 cells treated with DMSO or with 100µM 529 Propranolol (Propra) to inhibit Lipin-1 phosphatidate phosphatase activity (a), or transfected with 530 control (siCo.) and Lipin-1 siRNA (siLipin-1) (b). Data are relative to GAPDH levels; mean expression in controls was set to 1, and all other samples are relative to this ( $n \ge 4$  independent biological samples 531 532 per condition; multiple unpaired Student's t-tests). c, LDLR-luciferase in MDA231 cells transfected 533 with the indicated siRNA and treated with 100µM Propranolol (Propra). Mean expression in the control 534 was set to 1, and all other samples are relative to this  $(n \ge 4$  independent biological samples per 535 condition; unpaired Mann-Whitney tests). d, Immunofluorescence for endogenous SREBP2 in MCF10ATk1 cells treated with Propranolol, transfected with Lipin-1 or COPI siRNA, or expressing 536 dominant-negative ARF1-T31N-GFP (DN ARF1). Scale bar 10µm. n>50 cells per condition. e. Co-537 localization of transfected MYC-SCAP with the GFP-Rab6 Golgi marker in RPE1 cells treated 6 hours 538 539 with Propranolol, in cells transfected with control (siCo.), Lipin-1 or COPI siRNAs, or expressing dominant-negative ARF1-T31N (DN ARF1). Scale bar 10µm. n>50 cells per condition. f, Lipid 540 staining in MCF10ATk1 cells treated for 24 hours with YM, with 100µM Propranolol, or transfected 541 with Lipin-1 siRNA. Scale bar 5µm. Quantifications and n are provided in Supplementary Table 2. g. 542 543 Western blotting for Lipin-1 levels in microsomal fractions from MCF10ATk1 cells treated 3 hours 544 with DMSO or Y27632+ML7 (YM). Calreticulin (ER marker) and GM130 (Golgi marker) are loading controls. See also Supplementary Fig. 8. h, Co-localization of transfected GFP-PKD-KD with the 545 546 GM130 Golgi marker in HEK293 cells treated for 30 min with YM, with 100µM Propranolol, or 547 transfected with control (siCo.) and Lipin-1 siRNAs. Scale bar 10µm. Mean Pearson's correlation coefficient and SD for co-localization is indicated above each panel ( $n \ge 10$  cells were measured for 548 549 each condition). i, GST-GGA3-PBD pulldown for GTP-bound active ARF1 (GTP-Arf1) and western 550 blotting for ARF1 in the total extracts (Total Arf1). Cells were treated 3 hours with DMSO or YM. See 551 also Supplementary Fig. 8. j, Co-localization of endogenous ARF1 with a Golgi marker (GM130) in 552 MCF10ATk1 cells treated 6 hours with YM or Propranolol. Scale bar 10µm. Mean Pearson's 553 correlation coefficient and SD for co-localization is indicated above each panel (n>10 cells were 554 measured for each condition). The images in **d**-**j** are representative of at least two independent 555 experiments with similar results. All n values are pooled between independent experiments. Data are 556 mean and single points.

557

# 558 Figure 6. Actomyosin contractility regulates SREBP through Lipin-1.

a, Western blotting for transfected FLAG-tagged Lipin-1 in HEK293 cells treated with DMSO or YM

560 for 6 hours. The 17S/A mutant is not phosphorylated and migrates faster than WT Lipin-1. GAPDH

serves as loading control. See also Supplementary Fig. 8. **b**, Immunofluorescence for transfected

562 FLAG-Lipin-1 in MCF10ATk1 cells treated 6 hours with YM, Blebbistatin, or plated on a soft

hydrogel. Scale bar 10μm. n>50 cells per condition. c, Immunofluorescence for transfected wild-type
 (WT) or 17S/A FLAG-tagged Lipin-1 isoforms in RPE1 cells, treated with DMSO, YM or Torin1

- 565 (500nM) for 6 hours. Fusion with the membrane-localization domain of Syntaxin5 tethers MB-Lipin-1
- to cytoplasmic membranes. Scale bar  $10\mu$ m. n>50 cells per condition. Similar results were obtained

- 567 with MB\*-Lipin-1 (used in **d**) and in other cell lines. **d**, *LDLR-luciferase* (top) and *FASN-luciferase*
- 568 (bottom) assays in MDA231 cells treated with the ROCK/MLCK inhibitor FM and transfected with
- 569 wild-type (WT), membrane-tethered (MB and MB\*) or 17S/A Lipin-1 isoforms. **e**, *LDLR-luciferase*
- (top) and *FASN-luciferase* (bottom) assays in MDA231 cells transfected with the C3 RHO inhibitor
   without or with membrane-tethered (MB) Lipin-1. In **d** and **e**, mean expression in the control was set to
- 572 1, and all other samples are relative to this;  $n \ge 4$  independent biological samples per condition; unpaired
- 573 Mann-Whitney tests. **f.** MDA231 cells were transfected with WT-Lipin-1 or MB-Lipin-1 together with
- mCherry (RFP), treated with YM, and stained for cholesterol. n>30 cells per condition. Graph: cells
- 575 were scored positive (+ve) for Filipin based on the presence/absence of cytoplasmic cholesterol
- 576 accumulation. The images in **a**, **b**, **c** and **f** are representative of at least two independent experiments 577 with similar results. All n values are pooled between independent experiments. Data are mean and
- 577 with similar results. All 1 578 single points.
- 579

## 580 Figure 7. The Golgi apparatus responds to extracellular physical cues and intracellular force 581 application.

582 a, Co-localization of transfected MYC- SCAP with the GFP-Rab6 Golgi marker in RPE1 cells freely 583 spreading on fibronectin-coated glass (Large) or plated on micropatterned fibronectin islands restraining cell area and inducing low F-actin tension (Small, 960um<sup>2</sup> or 490um<sup>2</sup>). Scale bar 10um. 584 n>30 cells per condition. **b**, Golgi rheology was measured in RPE1 cells plated as in **a**. GFP-Rab6-585 586 positive Golgi membranes were pushed towards a cytoplasmic bead immobilized by an optical trap in a series of five 0.5µm steps in 1 min (see Supplementary Fig. 7a and Methods). The graph shows the 587 588 averaged displacements of the bead during the first step (see Supplementary Fig. 7b for the complete 589 graph). Green line: large unconfined cells, conditions of high tension (n=39 cells). The Golgi 590 microenvironment displays a visco-elastic behavior as the bead is first maximally displaced (Bead Step 591 Amplitude), and then slowly relaxes back due to attraction from the optical trap. Orange and Red lines: 592 micropatterned small ECM (n=28, 21 cells). Grav shadows: s.e.m. error bars. A smaller displacement 593 and a faster relaxation of the bead indicate a lower rigidity of the Golgi apparatus. c, The Rigidity 594 Index (RI) measures the friction opposed by the Golgi microenvironment on the bead, with lower 595 values indicating a softer microenvironment. The Bead Step Amplitude corresponds to the average 596 displacement of the bead after each step, with lower values indicating a softer microenvironment. The 597 Ejection Frequency measures the relative frequency of experiments in which the bead falls off the 598 optical trap, which is increased with the resisting friction forces applied on the bead by the Golgi. d, 599 Time-lapse confocal images of a representative RPE1 cell transfected with the GFP-PKD-KD 600 diacylglycerol sensor and with a Golgi-localized mCherry. A 2µm-diameter cytoplasmic bead (yellow 601 dotted line) was immobilized by an optical trap in the proximity of the Golgi apparatus (t=0) and then 602 pushed every 5 min. towards the Golgi (white arrow: direction of the compressive constraint). e. 603 Normalized intensity of the PKD-KD signal before and after application of force (n=19 cells). In the 604 control the bead was moved away from the Golgi towards the cytoplasm (n=18 cells). The images in  $\mathbf{a}$ 605 and **d** are representative of at least two independent experiments with similar results. All n values are pooled between independent experiments. Data are mean and s.e.m.; two-tailed unpaired Student's t-606 607 tests.

## 1 Methods

3 Reagents. Plasmids encoding for SCAP-MYC, HA-S1P, HA-S2P were from Y. Chen (SIBS 4 Shanghai), Perilipin3-RFP from L. Scorrano (UniPd), kinase-dead GFP-PKD1-K612W from A. 5 Hausser (UniStuttgart), ARF1-T31N-GFP from A. DeMatteis (TIGEM Naples), KDEL-mCherry from 6 E. Greotti (UniPd), GFP-OSBP from N. Ridgway (UniGlasgow). Addgene plasmids: FASN-lux #8890; 7 LDLR-lux #14940; 8XGTIIC-lux #34615; NF2 #19701; CMV-Luc2P ARE #62857; constitutiveactive FLAG-SREBP2 #26807; FLAG-Lipin-1 WT #32005 and 17S/A #32007; mCherry-8 9 Golgi(B4GALT1) #55052. Full length SREBP1 and SREBP2 were subcloned from Addgene plasmids #32017 and #32018. ER/Golgi membrane-tethered Lipin-1 isoforms were obtained by in-frame fusion 10 of the Syntaxin5 delta220 or TMD fragments<sup>53,54</sup> to FLAG-Lipin-1 WT and have been deposited as 11 Addgene plasmids #120277 and #120278. SUMOylation (K616/646A) and acetylation (K476/646A) 12 FLAG-Lipin-1 mutants were obtained by targeted mutagenesis. All plasmids were sequence-verified 13 14 before use and transfected as endotoxin-free maxi preps.

15 Small molecule inhibitors were: Y27632 (Axon 1683, 20 microM, 10 microM on hPSC); Fasudil/HA1077 (SantaCruzBiotechnology sc358231, 20 microM); ML7 (Sigma I2764, 20 microM); 16 17 Blebbistatin (Sigma B0560, 20 microM); Propranolol (Sigma P0884, 100 microM); Cycloheximide 18 (Sigma C1988, 100 microg/ml); TOFA (Sigma T6575, 15 microM, 75 nanoM on hPSC); Cerivastatin (Sigma SML0005, 10 microM, 25 nanoM on hPSC); 25-hvdroxy-cholesterol (Sigma SML2042, 30 19 20 microM, 1.25 microM on hPSC); U18666A (SantaCruzBioTechnology sc203306, 3 microM); 21 PF429242 (Sigma SML0667, 10 microM); Z-VAD-FMK (Sigma V116, 30 microM); Torin1 (Axon 22 1833, 500 nanoM); MG132 (Sigma C2211, 10 microM); MG115 (Sigma C6706, 10 microM).

23 siRNAs were selected among FlexiTube GeneSolution 4 siRNA sets (Qiagen) and reordered 24 after validation as dTdT-overhanging 19nt RNA duplexes (Thermo). siRNA sequences: SREBF1a 25 CGGAGAAGCUGCCUAUCAA; SREBF1b GCGCACUGCUGUCCACAAA; SREBF1c 26 GCGCACUGCUGUCCACAAA; SREBF1d ACAGCAACCAGAAACTCAA; SREBF2a 27 GCAGUGUCCUGUCAUUCGA; SREBF2b GCAAUUUGUCAGUAAUCAA; SREBF2c 28 GGCCAUUGAUUACAUCAAA; SREBF2d CGAUAUCGCUCCUCCAUCA; **SCAPa** 29 GGAAGAUCGACAUGGUCAA; LPIN1 SCAPb GGCCGACGCUCUUCAGCUA; 30 GUUCGGAUACCUUCAGUAA; YAP CUGGUCAGAGAUACUUCUU; TAZ Ref.<sup>55</sup>: 31 AGGUACUUCCUCAAUCACA; AMPKa1/2 mixes and b see COPIa а

GAUUUACCGAGGAGCAUUA; COPIb GGAUCGCUUGAUAGAAUUA; AllStars Negative
 Control (Qiagen) sequence not available – proprietary information.

34

35 Cell cultures. MCF10A, MCF10ATk1 MCF10ATk1 pBABE mTAZ 4SA were cultured in 36 DMEM/F12 5%HS Insulin (Sigma) Cholera Toxin (Sigma) hEGF (Peprotech) and Hydrocortisone 37 (Sigma). GFP-Rab6 and parental RPE1 in DMEM/F12 10%FBS (neomycin for GFP-Rab6). MDA-38 MB-231 in DMEM/F12 10%FBS. HEK293 in DMEM 10%FBS. WI-38 in MEM 10%FBS 5% oxygen. 39 3T3-L1 in DMEM 10%FBS 5% oxygen. H9 hPSC in E8 medium (DMEM/F12, NaHCO3, Insulin, 40 Selenium, Transferrin, L-ascorbic acid, FGF2, TGFb1) 5% oxygen. WT and AMPKa1/2-/- MEFs in 41 DMEM 20%FBS. Glutamine was freshly added to a final concentration of 20mM to all media. General media, serum and supplements were from Thermo. Cytokines from Sigma and Peprotech. All cell lines 42 43 were routinely tested with ATCC Universal Mycoplasma Detection kit to exclude contaminations. Cells for immunofluorescence in a stiff microenvironment were plated on fibronectin-coated glass 44 45 coverslips. Stiff (E≈15KPa) and soft (E≈0.5KPa) fibronectin-coated polyacrylamide hydrogels were assembled in-house by standard protocols. Annular-shaped micropatterns (25 or 35µm diameter, 5µm 46 47 line thickness) were printed on PEG-coated glass coverslips by deep UV photolithography and coated 48 with 50µg/ml fibronectin supplemented with 20µg/ml Alexa647-fibrinogen (Sigma). hPSC were

dissociated with Tryple (Thermo) and plated as single cells (2500 cells/2cm<sup>2</sup> well) in the presence or absence of the indicated small molecules for 24 hours; medium was then changed and cells were left growing for 4-5 days, until the appearance of macroscopic colonies. Treatment of colonies was done on colonies grown from single cells as above, and then treating for 24 hours. Cell transfections were carried out with Transit-LT1 (MirusBio) or with Lipofectamine RNAi-MAX (Thermo).

54

55 Antibodies, immunofluorescence and stains. See Supplementary Table 1 for catalog numbers, dilutions and validations. For the SREBP2 antibodies, independent lots were used with consistent 56 results. Immunofluorescence was performed as in<sup>56</sup> with minor modifications: 10min 1.5mg/ml glycine 57 in PBS before permeabilization to reduce background; blocking in 1-2% BSA. Images were acquired 58 59 sequentially with a Zeiss LSN700 or a Leica SP5 confocal microscope equipped with a CCD camera 60 using ZEN 2 or Leica LAS AF softwares. Typical acquisition settings for IF were: image size 61 1024x1024 pixels; acquisition mode xyz; pixel size 0.15µm; image depth 8 bits; acquisition speed 5/10, 62 with average 2; Plan-Apochromat 63x/1.40 oil DIC M27 objective. For multichannel acquisitions, we 63 used a main beam splitter 405/488/555/639. Raw images (saved in .czi or .lif formats) were opened in 64 ImageJ and saved in exportable formats. If needed, colors were changed (e.g. red to green) with 65 Photoshop CC.

66 Oil Red-O staining (Sigma) was carried out after fixation, in 60% v/v isopropanol/water. C11-67 Bodipy581/591 (Thermo) were incubated 15min with cells before FACS analysis. Filipin staining was 68 acquired using a UV filter set (340/380nm excitation, 40nm dichroic, 430nm long pass filter) by 69 prefocusing cells based on TOTO3 nuclear counterstain (633/647nm) and then acquiring the UV 70 channel without prior observation to avoid photobleaching. Typical acquisition settings for Filipin were: image size 1024x1024 pixels; acquisition mode xyz; pixel size 0.15µm; image depth 8 bits; 71 72 acquisition speed 5/10, with average 2; Plan-Apochromat 63x/1.40 oil DIC M27 objective. Pictures 73 were always taken by using the same acquisition conditions between all different experimental 74 samples; panels are representative pictures based on at least two independent experiments. 75 Quantifications and n are provided in Supplementary Table 2.

Alkaline phosphatase staining was Leukocyte AP kit (Sigma). Panels shown are representative pictures of one biological replicate of one experiment; each experiment was repeated three times independently. Quantifications and n are provided in Supplementary Table 2.

80 Cell fractionation, western blotting and pulldown. Nuclear extracts and microsomes were obtained 81 by resuspending cells in lysis buffer (250mM Sucrose, 10mM Triethanolamine pH=7.4, 10mM 82 AceticAcid, 1mM EDTA, 10mM KCl) and passing cells 8 times (i.e. complete lysis at the microscope) 83 through an Isobiotec Cell Homogenizer with a 6micron clearance sphere. Lysates were centrifuged at 800rcf to isolate nuclei, and then at 100.000rcf to isolate microsomes. Western blotting was performed 84 as in Ref<sup>57</sup>; in Fig. **3e** and Supplementary Fig. **3h** cells were incubated with 10microM MG132/MG115 85 proteasome inhibitors during treatment to prevent degradation of cleaved SREBPs. Active GTP-bound 86 87 ARF1 pulldown was performed with a commercial kit following the manifacturer's intructions 88 (Cytoskeleton Inc. BK032).

89

**Gene expression studies.** Luciferase assays were performed in MDA-MB-231 cells as in Ref.<sup>55</sup>. For qPCR, total RNA was isolated using commercial kits with DNAse treatment (Qiagen, Norgen). cDNA synthesis was carried out with M-MLV Reverse Trascriptase (Thermo) and oligo-dT primers. qPCR reactions were assembled with FastStart SYBR Green Master Mix (Roche) and run on a QuantStudio6 thermal cycler (Thermo). Gene expression levels for each biological sample was quantified as the mean between three technical replicates; *GAPDH* expression levels were used to normalize gene expression between samples, based on the  $2^{-\Delta\Delta Ct}$  method.

97 Sequences of primers: ACSS2 For GTT GAC TCC CCT TCC TGG TG, Rev CTT CCA ACT 98 CTT CCC CGG AC: CTGF AGG AGT GGG TGT GTG ACG Rev ACC AGG CAG TTG GCT CTA ATC; DHCR7 For CCG CCC AGC TCT ATA CCT TG, Rev ACT TGT TCA CAA CCC CTG CA; 99 FASN For GGA GGA GTG TAA ACA GCG CT, Rev TTG GCA AAC ACA CCC TCC TT; HMGCR 100 101 For TGC AGC AAA CAT TGT CAC CG, Rev CAC CAC CCA CCG TTC CTA TC; HMGCS1 For 102 ACA CAA GAT GCT ACA CCG GG, Rev ATG GGT GTC CTC TCT GAG CT; LDLR For AAG 103 GAC ACA GCA CAC AAC CA, Rev AAA GGA AGA CGA GGA GCA CG; LPN1 For ACA TGG ATC CTG AAG TGG CG, Rev GAG ATG GCG ATG GAA GGG AG; SQLE For AGG CGC AGA 104 105 AAA GGA ACC AA, Rev GCC AGC TCC CAC GAT GAT AA; SCD For CCA CTT GCT GCA GGA CGA TA, Rev CCA AGT AGA GGG GCA TCG TC; SREBF1 For CGT TTC TTC GTG GAT 106 GGG GA, Rev CCC GGA ATA GCT GAG TCA CC; SREBF2 For GGG CTG GTT TGA CTG GAT 107 GA, Rev AGA TCT GCC TGT TTC CGG TG; SCAP For CAG CAG CAA CAC AGT GAC CT, Rev 108 TAT GGT CTT GGC TCC CTG TC; GAPDH For CTC CTG CAC CAC CAA CTG CT, Rev GGG 109 CCA TCC ACA GTC TTC TG; COPI For AGT ACA GCC TGA TGA CCC CA, Rev TGC TGC CTC 110 TTT CCT CTG TG; AMPKa1 For CTT GCC AAA GGA GTG ATT CAG ATG C, Rev AGG TCA 111 ACA GGA GAA GAG TCA AGT GT; AMPKa2 For AGC GTT CCT GTT CTG CTG CT, Rev TCC 112 113 ATG GTG TGA CTG CCC AG.

114 Microarray probe synthesis, hybridization and detection were performed at CMB Trieste on HumanHT-12 v4 Expression BeadChips with an Illumina Hiscan system. Data analyses were 115 performed in R (version 3.0.2) using Bioconductor libraries (BioC 2.13) and R statistical packages. 116 117 Probe level signals were converted to expression values using robust multi-array average procedure RMA<sup>58</sup> of Bioconductor Affymetrix package. Differentially expressed genes were identified using 118 Significance Analysis of Microarray (SAM) algorithm coded in the same R package<sup>59</sup>. In SAM, we 119 estimated the percentage of false-positive predictions (i.e., false discovery rate, FDR) with 100 120 121 permutations. Genes activated or inhibited upon YM treatment and used for Gene List Enrichment Analysis were filtered based on *P*-value<0.05 and fold change>1.3. Gene List Enrichment Analysis 122 was performed with Enrichr<sup>60</sup>. SREBP target genes were defined based on Ref.<sup>61,62</sup>. 123

124

Metabolomics and metabolic analyses. Large-scale metabolic analysis (global metabolomics) and 125 126 Principal Component Analysis of the results was carried out by Metabolon Inc. Mechanosensitive MCF10Tk1 cells<sup>56</sup> were washed once in warm 1XPBS, and metabolites were extracted 5 min at RT on 127 128 15cm plates with 80% v/v Methanol/Water extraction buffer with internal standards. We harvested 129 cells on plate to specifically avoid alteration of actin tension and of metabolism due to cell detachment. 130 Metabolites were normalized to protein content. This analysis did not focus on triglyceride content. Clustering of selected lipid metabolites (fold change>2.5; p-value<0.05) shown in Supplementary Fig. 131 132 1e was carried out with Heatmapper.

133Targeted lipidomic analysis was carried out on MCF10Tk1 cells lysed in 1:1 v/v134MeOH/Acetonitrile extraction buffer by tissue lyser and spun at 20,000g for 5 min at 4°C. Supernatant135were then passed through a regenerated cellulose filter, dried and resuspended in 100µl of MeOH.

136 For the quantification of the different phospholipid species the liquid chromatography tandem mass spectrometry LC-MS/MS analysis was performed on API-4000 triple quadrupole mass 137 138 spectrometer (AB Sciex) coupled with a HPLC system (Agilent) and CTC PAL HTS autosampler (PAL System). The identity of the different phospholipid families was confirmed using pure standards, 139 namely one for each family. Methanolic extracts were analyzed by a 5 minutes run in both positive and 140 141 negative ion mode with a 275 multiple reaction monitoring (MRM) transitions in positive mode and 92 142 MRM transitions in negative mode. Quantification of different phospholipids in positive ion mode was performed using a Synergi 4µ Hydro-RP (50mm x 2.0mm, 4µm; Phenomenex) and in negative ion 143 144 mode using Cvano-phase LUNA column (50mm x 4.6mm, 5µm; Phenomenex). The mobile phase for positive ion mode was 0.1 % formic acid in MeOH and 5 mM ammonium acetate pH 7 in MeOH for negative ion mode both with a with a flow rate of 500µl/min. MultiQuant<sup>™</sup> software version 3.0.2 was used for data analysis and peak review of chromatograms. Semi-quantitative evaluation of different phospholipids was performed based on external standards, then data were normalized on protein content assessed by BCA method.

150 For the quantification of the different diacylglycerol and triacylglycerol species the liquid 151 chromatography tandem mass spectrometry LC-MS/MS analysis was performed on API-4000 triple 152 quadrupole mass spectrometer (AB Sciex) coupled with a HPLC system (Agilent) and CTC PAL HTS 153 autosampler (PAL System). Methanolic extracts were dried under nitrogen and resuspended in 100ul of 154 65% Acetonitrile/30% isopropanol/5% water. Samples were then analyzed by a 10 minutes run in positive ion mode with a 92 multiple reaction monitoring (MRM) transitions. Quantification of 155 156 different diacylglycerols and triacylglycerols was performed using a XBridge<sup>™</sup> C-18 (100mm x 2.1mm, 3.5um; Waters). Column temperature was set at 55°C. The mobile phases were phase A: 40% 157 158 acetonitrile, 0.1 % formic acid and 10 mM ammonium acetate in water; phase B: isopropanol 90%, 159 acetonitrile 10%, 0.1 % formic acid and 10 mM ammonium acetate. T<sub>0</sub>: 55%A; T<sub>2min</sub>: 55%A; T<sub>4min</sub>: 3%A; T<sub>7min</sub>: 3%A; T<sub>7 1min</sub>: 55%A; T<sub>10min</sub>: 55%A; with a flow rate of 260µl/min. MultiQuant<sup>™</sup> software 160 version 3.0.2 was used for data analysis and peak review of chromatograms. Semi-quantitative 161 162 evaluation of different diacylglycerols and triacylglycerols was performed based on external standards, 163 then data were normalized on protein content assessed by BCA method.

For isotopolog analysis, cells were exposed to 2.5 mM [ $^{13}C_2$ ]acetate (Sigma 282014) for 24h. 164 After removing media, cells were washed in ice-cold PBS. Lipid extraction was performed by adding 165 166 500µl of MeOH/ACN (1:1 v/v), and then 2.5ml of chloroform-MeOH (1:1, v/v). Total FAs were obtained by acid hydrolysis adding 1.25ml of HCl 1M and 1.25ml of MeOH. After leaving samples 1h 167 168 in agitation at 210 rpm, 2.5ml of chloroform-water (1:1, v/v) were added to the mixture and the lower organic phase was collected, split, transferred into tubes, and dried under nitrogen flow. The residue 169 170 was resuspended in MeOH/H<sub>2</sub>O (1:1, v/v) and used for total FA analysis. Sample were analyzed by and 171 API 4000 mass spectrometer (AB Sciex) coupled with a HPLC system (Agilent) and CTC PAL HTS 172 autosampler (PAL System). The gradient (flow rate 0.5 ml/min) was as follows: T0: 20% A, T20: 1% A, T25: 1% A, T25.1: 20% A, T30: 20% A, where A: acetic acid 15mM and N-ethylisopropylamine 173 10mM in H<sub>2</sub>O:MeOH 97:3 and B: MeOH. The Hypersil GOLD<sup>TM</sup> column (C8 100mm x 3mm, 3µm; 174 175 Thermo-Scientific) was maintained at 40°C for all the analysis.

For the quantification of free and total fatty acids and cholesterol levels, we used an aliquot of
extracts described above and commercial kits (Sigma MAK044 and MAK043) following the
instructions.

179

180 Intracellular optical micromanipulation, microrheological measurements and analysis. The set-up combining optical trapping and confocal imaging was described previously<sup>47</sup>. Briefly, red fluorescent 181 580/605nm 2µm diameter latex beads (Thermo F88265) were endocytosed overnight in RPE1 cells 182 stably expressing the Golgi marker GFP-Rab6. The incubation time and bead concentration were 183 184 adjusted so that cells typically contained one or two beads before optical micromanipulation. Cells 185 were plated on 18mm diameter coverslips uniformly coated with fibronectin, or with annular-shaped adhesive fluorescent micropatterns of different diameters (25 or 35 µm), during 6 hours. Non-adherent 186 cells were washed off by rinsing with culture medium. The coverslip was then mounted in a Ludin 187 188 chamber and the culture medium was supplemented with 20mM Hepes prior to the experiment.

Force was applied on GFP-positive Golgi membranes by first trapping a bead located close to the Golgi apparatus and then displacing the microscope stage in order to push the organelle against the trapped bead. Trapping was not possible on polyacrilamide hydrogels because of the excessive distance 192 between lens and cells in this set-up. The applied force F was deduced from the bead displacement relative to the trap center  $\Delta x$  after calibration of the trap stiffness  $k_{trap}$  using  $F = k_{trap} \Delta x$  with 193  $k_{trap} = 280 \text{ pN/}\mu\text{m}$ . The output power of the infra-red laser at the objective aperture was 150 mW. 194 Stage displacement was performed using a nanopositioning piezo-stage (Nanobio 200, Mad City Labs) 195 196 controlled by the NanoRoute3D software (Mad City Labs). The stage displacement consisted in five 197 consecutive 0.5µm steps with a 10s pause between each step to allow visco-elastic relaxation of the 198 bead position towards the trap center. The total duration of optical trapping was limited to 1 min for a 199 given cell to ensure cell viability.

To characterize the rigidity of the microenvironment surrounding the bead, we used a phenomenological analysis of the relaxation curves as in<sup>47,63</sup> to measure three parameters: the 200 201 202 frequency of bead ejection, the bead step amplitude and the rigidity index. Qualitatively, in a low rigidity microenvironment, friction on the bead is low and the bead does not move much from the trap 203 204 center during the step displacement and relaxes rapidly towards the trap center. In a rigid 205 microenvironment, the bead experiences a high friction and its initial displacement is bigger and closer 206 to the step displacement (0.5µm) and the relaxation is slower. If the force acting on the bead is too 207 large (typically above 300-400pN), the bead falls off the trap and subsequently follows the 208 displacement of the stage. We termed such events 'ejections' and scored their frequency (defined as the 209 ratio between the number of experiments in which ejection occurred and the total number of 210 experiments) and the step at which ejection occurred. The bead step amplitude X<sub>b</sub> corresponds to the displacement of the bead after a 0.5µm step of the piezo-stage. Values of X<sub>b</sub> close to 0.5µm indicate a 211 high rigidity of the bead microenvironment. Lower values are indicative of softer microenvironments. 212 213 The rigidity index is defined as

$$RI = \frac{\int_{t_i}^{t_i + T} x_b(t) dt}{\int_{t_i}^{t_i + T} x_s(t) dt} = \frac{\int_{t_i}^{t_i + T} x_b(t) dt}{X_s T}$$

where  $t_i$  is the time when the i<sup>th</sup> 0.5 µm step displacement of the piezo-stage occurs,  $x_b$  and  $x_s$  are respectively the displacement of the bead relative to the trap center and the displacement of the piezostage,  $X_s = 0.5$ µm is the amplitude of the piezo-stage step and T = 10s is the duration of the step. The rigidity index RI is a phenomenological parameter which allows us to compare the rigidity of the microenvironment surrounding the bead in various conditions. The value of RI falls between 0 (the microenvironment does not exert any friction on the bead) and 1 (the microenvironment is not deformable). The values of RI for each step displacement were averaged.

221 To measure GFP-PKD-KD recruitment upon force application, cells were plated at day 1 in a 222 12-well plate to reach around 75% confluence on day 2. At day 2, cells were transfected with GFP-223 PKD-KD and mCherry-Golgi(B4GALT1) plasmids. At the end of day 2, the cells were incubated with 224 2µm diameter fluorescent beads overnight. At day 3, cells were transferred to fibronectin-coated 225 coverslips for the experiment. The evolution of normalized intensity of GFP-PKD-KD in the region of 226 the Golgi apparatus, visualized by the mCherry-Golgi marker, was monitored after application of a 227 mechanical constraint exerted by internalized beads trapped with optical tweezers. A bead located near 228 the Golgi apparatus was selected in a cell expressing GFP-PKD-KD and the mCherry-Golgi marker. A 229 first image was taken at t=0min. The bead was then trapped with the optical tweezers and the 230 microscope stage manually displaced to bring the Golgi apparatus in contact with the bead and apply a 231 compressive constraint on the Golgi apparatus during 1 min. The same protocol was repeated every 232 5min until t=30min. The duration of the compressive constraint was reduced to 30s after t=10min to 233 avoid cellular damage due to prolonged laser exposure. As a control, the same protocol was used but 234 the microscope stage was displaced in order to move the bead away from the Golgi apparatus.

To quantify the fluorescence intensity of GFP-PKD-KD in each of the seven images taken every 5 minutes, the Golgi apparatus was delimited using the mCherry Golgi marker. The total intensities of the mCherry Golgi marker ( $I_r$ ) and of GFP-PKD-Kd ( $I_g$ ) were measured as well as the mean intensity of the background for each channel ( $\langle I_{r back} \rangle$  for the mCherry Golgi marker and  $\langle I_{g back} \rangle$  for GFP-PKD-KD) and the area of the Golgi apparatus  $A_{Golgi}$ . The total intensity of the background in the Golgi apparatus region for each channel was then estimated by multiplying the mean background intensity by the Golgi area:

$$\begin{split} I_{r \; back} &= A_{Golgi} \; . \; \langle I_{r \; back} \rangle \\ I_{g \; back} &= A_{Golgi} \; . \; \langle I_{g \; back} \rangle \end{split}$$

The fluorescence intensity of GFP-PKD-KD was normalized by the fluorescence intensity of the mCherry Golgi marker:

$$I = \frac{I_g - I_{g \text{ back}}}{I_r - I_{r \text{ back}}}$$

to account for slight changes in the imaging plane from one image to the next. The relative temporal variations of the GFP-PKD-KD fluorescence were obtained by normalizing the intensity I measured from each image taken every 5 minutes by its initial value  $I_0$ :  $I(t) = I/I_0$ .

248 Statistics and Reproducibility. All data are based on independent experiments with independent 249 biological replicates, except for metabolomics and microarrays that were based on independent 250 biological replicates harvested in a single experiment. Experimental repetitions were carried out by 251 thawing a new aliquot of cells, deriving from the original stock. Key data were independently 252 replicated by two different operators, across different cell lines, and with independent techniques 253 providing coherent results. All n values are pooled between independent experiments. Data are 254 presented as mean and single points, or mean and standard error of the mean (s.e.m.) as indicated in the 255 figure legends. Significance tests were unpaired non-parametric Mann-Whitney tests, unpaired twotailed Student's t-tests, multiple unpaired two-tailed Student's t-tests with Holm-Sidak correction (for 256 257 analysis of multiple qPCR markers), or Welch's two sample t-tests (for global metabolomics). t-tests 258 have been performed under the reasonable assumption that values follow a normal distribution and 259 have similar variance.


260


## 261 **Code availability**


No custom codes were used in this study. All other codes are indicated in the appropriate methods sections and references.


264


Data availability. Microarray, metabolomics and targeted lipidomics data have been deposited (GEO database GSE107275 and Figshare database 10.6084/m9.figshare.7338764). Source data for Figs. 1-7
 and Supplementary Figs. 1-7 have been provided in Supplementary Table 2. All other data supporting the findings of this study are available from the corresponding author on reasonable request.


























f

**C**3

°°

00

MB

Lipin-1

P = 0.0002

MB

Lipin-1

**C**3

ഷി

